Georg Kelllinghusen (BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN))

Kellinghusen, Georg (BRAIN 202007 Chairman of Supervisory Board)

	Organisation	BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
	Today	BRAIN Biotech AG
	Group	BRAIN Biotech (Group)
	Product	industrial biotechnology

BRAIN AG. (7/7/20). "Press Release: Change in the Management Board of BRAIN AG. Chief Business Officer Ludger Roedder Is Leaving the Executive Board with Immediate Effect". Zwingenberg.

The biotechnology company B.R.A.I.N. Biotechnology Research and Information Network AG announces that Chief Business Officer Ludger Roedder will leave the executive board by mutual agreement with immediate effect on July 7th, 2020 due to different strategic visions. Mr. Roedder will leave the BRAIN AG at the end of the calendar year.

Dr Georg Kellinghusen, Chairman of the Supervisory Board, states: "We like to thank Ludger Roedder for his contribution and commitment to the development of the BRAIN AG since 2018 and wish him the most success for his next ventures. We feel very comfortable with the future setup of a two person’s board consisting of Adriaan Moelker, CEO, and Lukas Linnig, CFO. Currently we are not planning a succession for Ludger Roedder".

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe’s leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this “Toolbox of Nature” are successfully applied in the chemistry, the cosmetics and the food industries. BRAIN’s business model is based on two pillars. The BioScience segment comprises mainly of the research and development business with industrial partners (the “Tailor-Made Solutions” cooperation business), and the company’s own research and development. The BioIndustrial segment consists mainly of the industrially scalable products business. Further information is available at www.brain-biotech.com.
Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Media Contact

Dr. Stephanie Konle
pr@brain-biotech.com
+49 (0)6251-9331-70